Indiana commits $1 billion in tax credits to life sciences jobs in Eli Lilly's home region
Indiana is directing $1 billion in tax credits toward agriculture and life sciences employers, a push that names no medicine and leaves GLP-1 manufacturing questions open.
Indiana will steer $1 billion in state tax credits to agriculture and life sciences employers over the next decade under a plan Gov. Mike Braun rolled out Tuesday, with a stated goal of 100,000 high-wage jobs in those fields within 10 years [1].
The money moves through the Indiana Economic Development Corporation and is the first industry-specific commitment of its kind. It follows a Braun executive order issued last year that told Indiana's 15 economic regions to draft formal growth plans covering jobs, per capita income and educational attainment [1].
Credits are conditional, and Commerce Secretary David Adams said they can go only to positions paying at least 125% of the median wage in the county where the job is located [1]. The $1 billion accounts for roughly a third of the tax credits the IEDC has on hand, Adams said [1].
Braun named the Central Indiana Regional Development Authority, or CIRDA, as the first regional steward to run the program [1]. Eli Lilly, Elanco Animal Health and Corteva Agriscience already operate in that region [1].
"Indiana is the leader in life sciences," Braun said at the announcement. "We are the premier destination for human therapeutics, animal health, agri-tech, biotechnology and environmental innovation" [1]. The state, he said, "will be an epicenter for reshoring and expansion in this area" [1].
Braun tied the focus on agriculture and life sciences to pay levels. "It's a growth industry," he said. "Other states are trying to corner that market" [1].
The initiative grows out of the Regional Economic Acceleration and Development Initiative, or READI, which funded quality-of-place projects [1]. Adams said Braun "recognized that the state is not one economy, but a series of regional economies," and that each region was asked to identify the sectors that are core strengths locally [1].
CIRDA is the first region to produce a strategy, built around human, animal and plant health [1]. Fishers Mayor Scott Fadness said central Indiana has the ability to discover, make, move and apply health products [1]. Stephen Ferguson, chairperson of the Cook Group, said in a statement that the life sciences sector creates jobs and opportunities for Hoosiers while delivering health solutions [1]. Vanessa Green Sinders, president and CEO of the Indiana Chamber of Commerce, called the investment a signal that the state is competing for talent and future private-sector growth [1].
Why it matters for patients
The plan names no medicine, no product and no therapeutic category [1]. GLP-1 drugs, obesity treatments, semaglutide and tirzepatide go unmentioned [1]. The only drugmaker identified is Eli Lilly, and only as an employer already present in the central region [1].
Whether any of the credits would build or expand manufacturing for a particular medicine, and whether that would shift supply or prices, has not been reported [1]. No link between the incentives and the availability or cost of any treatment has been disclosed.
What is established is the scale: about a third of the state's available tax credits, spread over 10 years, aimed at employers in fields that include human therapeutics [1]. Patients who track where their medicines are made will have to wait for the awards themselves to see which projects qualify.
What happens next
CIRDA's strategy is the first submitted under the 2025 executive order; no timetable has been disclosed for the other 14 regions [1]. No award dates, recipient list or per-company totals have been published [1]. A news page the IEDC set up for the announcement could not be reached [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.